MAPT and Alzheimer disease: Overall, in vitro and in vivo evidence (cross-sectional and longitudinal), although somewhat preliminary, suggest that tracers of the THK family, primarily, and, secondarily, [11C]PBB3, may be better suited than [18F]AV1451 for tracking non-AD tau pathology [26, 35, 113, 118–121], although the latter remains to be confirmed by ante-/post-mortem findings in CBS and PSP.